Cardurion is a cardiovascular biotechnology company developing therapeutics for the treatment of heart failure and cardiovascular diseases.
Cardurion Pharmaceuticals has raised $260.0M in total funding. The most recent round was Series B. The last funding was announced in July 2024.
Cardurion Pharmaceuticals's investors include New Enterprise Associates, Digitalis Ventures, Blue Owl, Polaris Partners, Bain Capital Life Sciences.
Cardurion Pharmaceuticals is headquartered in Boston, United States.
Cardurion is a cardiovascular biotechnology company developing therapeutics for the treatment of heart failure and cardiovascular diseases.
Cardurion Pharmaceuticals is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cardurion Pharmaceuticals — Funding & Investors." VCBacked, July 16, 2024, https://www.vcbacked.co/company/cardurion-pharmaceuticals. Accessed October 30, 2026.
VCBacked. (2024). Cardurion Pharmaceuticals — Funding & Investors. Retrieved October 30, 2026, from https://www.vcbacked.co/company/cardurion-pharmaceuticals
{{cite web |title=Cardurion Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/cardurion-pharmaceuticals |website=VCBacked |access-date=October 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated